Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Tax Provisions (2023 - 2025)

Historic Tax Provisions for Protalix BioTherapeutics (PLX) over the last 3 years, with Q3 2025 value amounting to -$175000.0.

  • Protalix BioTherapeutics' Tax Provisions fell 12883.03% to -$175000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 562777.78%. This contributed to the annual value of $1.2 million for FY2024, which is 6347.88% down from last year.
  • Protalix BioTherapeutics' Tax Provisions amounted to -$175000.0 in Q3 2025, which was down 12883.03% from $497000.0 recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Tax Provisions peaked at $3.4 million during Q2 2023, and registered a low of -$382000.0 during Q4 2023.
  • Moreover, its 3-year median value for Tax Provisions was $133000.0 (2023), whereas its average is $437727.3.
  • In the last 5 years, Protalix BioTherapeutics' Tax Provisions plummeted by 17076.92% in 2024 and then surged by 82028.99% in 2025.
  • Protalix BioTherapeutics' Tax Provisions (Quarter) stood at -$382000.0 in 2023, then soared by 315.18% to $822000.0 in 2024, then crashed by 121.29% to -$175000.0 in 2025.
  • Its Tax Provisions was -$175000.0 in Q3 2025, compared to $497000.0 in Q2 2025 and -$113000.0 in Q1 2025.